Kerkhof, MarjanVoorham, JacoDorinsky, PaulCabrera, ClaudiaDarken, PatrickKocks, Janwillem WHSadatsafavi, MohsenSin, Don D.Carter, VictoriaPrice, David B.2020-08-182020-08-182020-09-30Kerkhof, M, Voorham, J, Dorinsky, P, Cabrera, C, Darken, P, Kocks, J WH, Sadatsafavi, M, Sin, D D, Carter, V & Price, D B 2020, 'Association between COPD exacerbations and lung function decline during maintenance therapy', Thorax, vol. 75, no. 9, pp. 744-753. https://doi.org/10.1136/thoraxjnl-2019-2144570040-6376https://hdl.handle.net/2164/14945Acknowledgements: Writing and editorial support was provided by Dr Julia Granerod, supported by the Observational and Pragmatic Research Institute Pte. Ltd (OPRI). Funding: This study was funded by AstraZeneca.Data availability statement: Data may be obtained from a third party and are not publicly available. The dataset supporting the conclusions of this article was derived from the Clinical Practice Research Datalink (www.cprd.com) and the Optimum Patient Care Research Database (www.opcrd.co.uk). The CPRD has broad National Research Ethics Service Committee (NRES) ethics approval for purely observational research using the primary care data and established data linkages. The OPCRD has ethical approval from the National Health Service (NHS) Research Authority to hold and process anonymised research data (Research Ethics Committee reference: 5/EM/0150). This study was approved by the Anonymised Data Ethics Protocols and Transparency (ADEPT) committee – the independent scientific advisory committee for the OPCRD, and the Independent Scientific Advisory Committee (ISAC) for the CPRD. The authors do not have permission to give public access to the study dataset; researchers may request access to CPRD or OPCRD data for their own purposes. Access to CPRD can be made via the CPRD website (https://www.cprd.com/researcher/) or via the enquiries email enquiries@cprd. com. Access to OCPRD can be made via the OCPRD website(https://opcrd.co.uk/our-database/data-requests/) or via the enquiries email info@opcrd.co.uk. The study was designed, implemented, and registered in accordance with the criteria of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EUPAS19879).10735809engCOPD exacerbationsCOPD pharmacologyeosinophil biologylung physiologyOBSTRUCTIVE PULMONARY-DISEASEIMPACTBIOMARKERBLOOD EOSINOPHILSINHALED CORTICOSTEROIDSFEV1 DECLINER Medicine (General)Pulmonary and Respiratory MedicineR1Journal article10.1136/thoraxjnl-2019-214457http://www.scopus.com/inward/record.url?scp=85086718934&partnerID=8YFLogxK759